Fumarate Metabolic Signature for the Detection of Reed Syndrome in Humans.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 31636096.
- Also identified by DOI 10.1158/1078-0432.CCR-19-1729.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inherited pathogenic variants in genes encoding the metabolic enzymes succinate dehydrogenase (SDH) and fumarate hydratase predispose to tumor development through accumulation of oncometabolites (succinate and fumarate, respectively; ref. 1). Noninvasive <i>in vivo</i> detection of tumor succinate by proton magnetic resonance spectroscopy (<sup>1</sup>H-MRS) has been reported in SDH-deficient tumors, but the potential utility of this approach in the management of patients with hereditary leiomyomatosis and renal cell cancer syndrome or Reed syndrome is unknown. Magnetic resonance spectroscopy (<sup>1</sup>H-MRS) was performed on three cases and correlated with germline genetic results and tumor IHC when available. Here, we have demonstrated a proof of principle that <sup>1</sup>H-MRS can provide a noninvasive diagnosis of hereditary leiomyomatosis and renal cell cancer syndrome or Reed syndrome through detection of fumarate accumulation <i>in vivo</i>. This study demonstrates that <i>in vivo</i> detection of fumarate could be employed as a functional biomarker.
Medical subject headings
- Fumarates
- Germ-Line Mutation
- Kidney Neoplasms
- Leiomyomatosis
- Neoplastic Syndromes, Hereditary
- Proton Magnetic Resonance Spectroscopy
- Skin Neoplasms
- Uterine Neoplasms